Take medical use of cannabis seriously, say MEPs Press Releases , Plenary session , ENVI 13-02-2019 - 17:46 http://www.europarl.europa.eu/news/en/press-room/20190207IPR25221/take-medical-use-of-cannabis-seriously-say-meps The EU should stimulate innovation in medical cannabis Effective cannabis-based medicines should be covered by health insurance schemes Authorities should distinguish clearly between medical and other uses www.europarl.europa.eu/sides/getDoc.do?pubRef=-//EP//TEXT+TA+20190213+TOC+DOC+XML+V0//EN&language=EN MEPs propose ways to address research gaps on medical cannabis and call on member states to seize the potential of cannabis-based medicines. In a resolution adopted on Wednesday, MEPs call on the Commission and national authorities to draw a clear distinction between medical cannabis and other uses of cannabis. The resolution urges the Commission and member [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suiteClinical Manifestations of Cannabis Use Disorder Alan J. Budney, Jacob T. Borodovsky, and Ashley A. Knapp C Springer Nature Switzerland AG 2019 Introduction : Cannabis use disorder (CUD) or its colloquial synonym, cannabis addiction, remains controversial in that many in the general public believe that cannabis use does not pose substantial risk for harm and is not addictive in the same sense that tobacco, alcohol, cocaine, or heroin is addictive. Although assessment of people’s beliefs about addiction and harm is complicated by the lack of a consensus definition or a common understanding of addiction, the difference in perception of risk between cannabis and other [...]
Lire la suiteCannabidiol (CBD) : analyse de situation Frank ZOBEL, Luca NOTARI, Eva SCHNEIDER, Ocyna RUDMANN Addiction Suisse, Lausanne, janvier 2019 Rapport de recherche N° 97 https://www.addictionsuisse.ch/fileadmin/user_upload/DocUpload/Rapport-CBD-final.pdf Table des matières Liste des tableaux Liste des graphiques 1 Introduction 2 Méthode 3 Brève analyse de la littérature sur les effets du Cannabidiol (CBD) 3.1 Méthode 3.2 Usages du CBD et effets 3.3 Pourquoi prendre du CBD? Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine somatique Amélioration de la qualité de vie/réduction de certains symptômes dans le domaine psychique Traitement/prévention de maladies chroniques et neurodégénératives, renforcement du système immunitaire . Traitement de troubles neurologiques diagnostiqués . Autres 3.4 Que sait-on de ces effets à ce jour? 3.5 Le CBD peut-il [...]
Lire la suiteCannabis use and mental health: risks and benefits Wayne HALL, · Eva HOCH, · Valentina LORENZETTI European Archives of Psychiatry and Clinical Neuroscience, february 2019 https://doi.org/10.1007/s00406-019-00986-2 © Springer-Verlag GmbH Germany, part of Springer Nature 2019 In public debates about cannabis policy, two competing claims are often made about how cannabis use may affect mental health. One is that cannabis use by young adults and vulnerable individuals across the lifespan can be a contributory cause of : a cannabis dependence syndrome; schizophreniform psychoses; anxiety and depressive disorders; acute and perhaps chronic cognitive impairment, and structural and functional changes in brain pathways implicated in reward, learning and [...]
Lire la suiteThe neurobiology of addiction George R. Uhl, George F. Koob, and Jennifer Cable ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2019 Special Issue: Addiction Reviews https://doi.org/10.1111/nyas.13989 Substance and alcohol use disorders impose large health and economic burdens on individuals, families, communities, and society. Neither prevention nor treatment efforts are effective in all individuals. Results are often modest. Advances in neuroscience and addiction research have helped to describe the neurobiological changes that occur when a person transitions from recreational substance use to a substance use disorder or addiction. Understanding both the drivers and consequences of substance use in vulnerable populations, including those whose brains are [...]
Lire la suiteMarijuana, National Institute on Drug Abuse (NIDA), June 2018 Table of Contents Marijuana Letter From the Director What is marijuana? What is the scope of marijuana use in the United States? What are marijuana effects? How does marijuana produce its effects? Does marijuana use affect driving? Is marijuana addictive? What are marijuana's long-term effects on the brain? Is marijuana a gateway drug? How does marijuana use affect school, work, and social life? Is there a link between marijuana use and psychiatric disorders? What are marijuana's effects on lung health? What are marijuana’s effects on other aspects of physical health? Is marijuana safe and effective as medicine? What are the effects of secondhand exposure to marijuana smoke? Can marijuana [...]
Lire la suiteLe trouble stress post-traumatique et son traitement : au sujet d’une observation. François-Rodolphe INGOLD, GRECC, PARIS Charles D. KAPLAN, UCLA, Los Angeles Christian SUEUR, GRECC, LYON Intervention au Colloque UFCM I-care, Paris, Hôpital de La Salpétrière, 1er juin 2018. AVANT PROPOS La question de ce qu’il est convenu d’appeler le « cannabis thérapeutique », mis à part ses enjeux politico-économiques, est loin de se limiter au cannabis lui-même, en tant que plante et en tant que substances actives. La découverte fondamentale des derniers travaux de recherche ne tient pas à l’identification d’un certain nombre de cannabinoïdes et de terpènes, elle tient à la mise à jour de tout un [...]
Lire la suiteLes méta-analyses et le cannabis, ou la négation du savoir clinique 21 Septembre 2011 Dr. Christian Sueur, Psychiatre, praticien hospitalier http://tdme.free.fr/?p=2730#annot8 A l’ère des méta-analyses, la clinique psychiatrique bat de l’aile…., Ce que l’on peut lire aujourd’hui sur les « dangers du cannabis » fournit un exemple étonnant de cette perte du savoir clinique. Et pourtant, bien des « méta-analystes » qui parfois, n’ont jamais vu un patient, sans vergogne, « disent le vrai », et emportent l’opinion avec eux, opinion et journalistes qui se font l’écho de ses assertions, sans même émettre la moindre critique vis-à-vis de ces « chiffres » érigés en « [...]
Lire la suiteAntidépresseur-like effect induced by Cannabidiol is dependent on brain serotonin levels. A.J. Sales, C. C. Crestani, F. S. Guimaraes, S. R.L. Joca, Progress in Neuropsychopharmacology & Biological Psychiatry, 2018 Aug 30; 86: 255-261. Doi: 10.1016/j.pnpbp.2018.06.002 https://www.ncbi.nlm.nih.gov/pubmed/29885468 PMID : 29885468 Abstract Cannabidiol (CBD) is a compound of Cannabis sativa with relevant therapeutic potential in several neuropsychiatric disorders including depression. CBD treatment has shown significant antidepressant-like effects in different rodent preclinical models. However, the mechanisms involved in CBD-induced antidepressant effects are still poorly understood. Therefore, this work aimed at investigating the participation of serotonin (5-HT) and/or noradrenaline (NA) in CBD-induced antidepressant-like effects in [...]
Lire la suite